Sign in
BLU Stock Price, Chart, Stats & News
BELLUS Health Inc.
Save
1.87B
Market cap
–
Current P/E
–
Forward P/E
BLU chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -21967104.08% |
Operating margin | -486768.75% |
Pretax margin | -475125.00% |
Net margin | -475500.00% |
Effective tax rate | -0.08% |
ROA | -18.66% |
ROE | -22.28% |
D/E | 0.00x |
Interest coverage ratio | -998.50x |
BLU valuation
P/E | – |
P/S | 116865.18x |
P/B | 4.35x |
P/CF | -22.06x |
P/FCF | -19.08x |
P/OCF | -22.06x |
PEG | -0.22x |
EV multiple | -26.88x |
About
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
Similar securities
Based on sector and market capitalization
Report issue